Futura Medical plc (FAMDF)
Futura Medical plc operates in the Biotechnology industry of the Healthcare sector, headquartered in Guildford, SU, GB. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $678,664. On trailing twelve-month figures it carries a trailing P/E of -0.31, a net margin of -158.2%. Its beta of 0.00 implies it has historically moved less than the broad market.
Futura Medical plc operates as a pharmaceutical firm specializing in the creation and advancement of consumer healthcare products. The company primarily targets the sexual health and pain management sectors. Its leading innovation is MED3000, a topical gel specifically formulated to treat erectile dysfunction. Additionally, Futura Medical offers a variety of pain relief solutions, including TPR100, a topical diclofenac gel; CBD100, a cannabidiol-based topical application; and TIB200, an ibuprofen topical gel. Established in 2001, the company is headquartered in Guildford, United Kingdom.
Futura Medical plc is most often compared with the following Healthcare names: